Teva to Present at the Bank of America 2024 Global Healthcare Conference
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced that its President and CEO, Richard Francis, will be presenting at the Bank of America 2024 Global Healthcare Conference. The presentation is scheduled for Thursday, September 19, 2024, at 8:15 AM British summer time (3:15 AM Eastern Time).
Interested parties can access a live webcast of the presentation through Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. For those unable to attend the live event, an archived version of the webcast will be made available within 24 hours after the live discussion concludes.
Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato che il suo Presidente e CEO, Richard Francis, parteciperà alla Conferenza Globale sulla Salute 2024 di Bank of America. La presentazione è programmata per giovedì 19 settembre 2024, alle 8:15 ora legale britannica (3:15 ora orientale).
Le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso il sito web delle Relazioni con gli Investitori di Teva all'indirizzo https://ir.tevapharm.com/Events-and-Presentations. Per coloro che non possono assistere all'evento dal vivo, una versione archiviata del webcast sarà disponibile entro 24 ore dalla conclusione della discussione dal vivo.
Teva Pharmaceutical Industries (NYSE y TASE: TEVA) ha anunciado que su Presidente y CEO, Richard Francis, presentará en la Conferencia Global de Atención Médica 2024 de Bank of America. La presentación está programada para jueves, 19 de septiembre de 2024, a las 8:15 AM, hora británica de verano (3:15 AM, hora del este).
Las partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web de Relaciones con Inversores de Teva en https://ir.tevapharm.com/Events-and-Presentations. Para aquellos que no puedan asistir al evento en vivo, se estará disponible una versión archivada del webcast dentro de las 24 horas posteriores a la conclusión de la discusión en vivo.
테바 제약 산업 (NYSE 및 TASE: TEVA)는 Richard Francis 회장 겸 CEO가 뱅크 오브 아메리카 2024 글로벌 헬스케어 컨퍼런스에서 발표할 것이라고 발표했습니다. 발표는 2024년 9월 19일 목요일 오전 8시 15분(영국 섬머 타임 기준, 동부 표준시 3시 15분)으로 예정되어 있습니다.
관심 있는 당사자는 Teva의 투자자 관계 웹사이트 https://ir.tevapharm.com/Events-and-Presentations를 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 실시간 행사에 참석할 수 없는 분들을 위해, 아카이브된 버전의 웹캐스트가 실시간 토론 종료 후 24시간 이내에 제공될 예정입니다.
Teva Pharmaceutical Industries (NYSE et TASE : TEVA) a annoncé que son président et directeur général, Richard Francis, fera une présentation lors de la Conférence mondiale sur les soins de santé 2024 de Bank of America. La présentation est prévue pour jeudi 19 septembre 2024, à 8h15, heure d'été britannique (3h15, heure de l'Est).
Les parties intéressées peuvent accéder à un webcast en direct de la présentation via le site web des relations avec les investisseurs de Teva à l'adresse https://ir.tevapharm.com/Events-and-Presentations. Pour ceux qui ne peuvent pas assister à l'événement en direct, une version archivée du webcast sera disponible dans les 24 heures suivant la fin de la discussion en direct.
Teva Pharmaceutical Industries (NYSE und TASE: TEVA) hat angekündigt, dass sein Präsident und CEO, Richard Francis, auf der Bank of America 2024 Global Healthcare Conference präsentieren wird. Die Präsentation ist für Donnerstag, den 19. September 2024, um 8:15 Uhr britischer Sommerzeit (3:15 Uhr Eastern Time) geplant.
Interessierte Parteien können über die Investor Relations-Website von Teva auf einen Live-Webcast der Präsentation zugreifen unter https://ir.tevapharm.com/Events-and-Presentations. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird innerhalb von 24 Stunden nach Abschluss der Live-Diskussion eine archivierte Version des Webcasts verfügbar sein.
- None.
- None.
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M. Eastern Time).
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| IR Contacts | Ran Meir | +1 (215) 591-8912 | |
| Yael Ashman | +972 (3) 914 8262 | ||
| Sanjeev Sharma | +1 (973) 658 2700 | ||
| PR Contacts | Kelley Dougherty | +1 (973) 832-2810 | |
| Eden Klein | +972 (3) 906 2645 |
FAQ
When is Teva's CEO presenting at the Bank of America 2024 Global Healthcare Conference?
How can I watch Teva's presentation at the Bank of America 2024 Global Healthcare Conference?
Will there be a replay available of Teva's presentation at the Bank of America conference?
What is Teva's stock symbol?
